KRAS/NRAS Gene Mutations and the Efficacy of Bortezomib-Based Triplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
Anna Sergeeva(National Medical Research Center for Hematology), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), С. М. Куликов(Ministry of Health of the Russian Federation), В. Л. Сурин(National Medical Research Center for Hematology), А. А. Крайзман(National Research Center for Hematology Russian Academy of Medical Sciences), M. V. Solovev(Ministry of Health of the Russian Federation), Ю. А. Чабаева(National Research Center for Hematology Russian Academy of Medical Sciences)
Cited by 1
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59